Updating CAR-T Cell Immunotherapy for Liquid and Solid Tumor
Journal Title: Diseases & Research - Year 2023, Vol 3, Issue 2
Abstract
According to the GLOBOCAN 2020 report, there is still a 50% mortality rate observed in cancer patients despite the availability of various innovative cancer therapies. This highlights the need for specific therapies that can effectively kill cancer cells without harming normal cells. One such therapy is cancer immunotherapy, which comprises immune checkpoint blockade, adoptive cellular therapies, cancer vaccines, and CAR-T cell therapy. CAR-T cell therapy entails modifying T-cells from a cancer patient in a lab so that they attack cancer cells only. This therapy has been successful in treating some lymphomas and myelomas, and is being explored for solid tumors as well. However, there are certain limitations to its efficacy for solid tumors due to their heterogeneity. This review covers the most recent advancements and enhancements in CAR-T therapies for lymphomas and solid tumors, as well as methods to get around their drawbacks.
Authors and Affiliations
Ankita Singh, Pravin D. Potdar
Keywords
Related Articles
- EP ID EP740180
- DOI 10.54457/DR.202302005
- Views 41
- Downloads 1
Salvage Therapy with Gilteritinib Plus Venetoclax for FLT3-ITD-Positive AML: A Case Report and Literature Review
FMS-like tyrosine kinase 3 (FLT3) mutations occur in around 30% of patients in acute myeloid leukemia (AML), and are generally associated with unfavorable outcomes. Gilteritinib is a highly specific second-generation cla...
Updating CAR-T Cell Immunotherapy for Liquid and Solid Tumor
According to the GLOBOCAN 2020 report, there is still a 50% mortality rate observed in cancer patients despite the availability of various innovative cancer therapies. This highlights the need for specific therapies that...
Incidence of Side Effects During Tenofovir Alafenamide Monotherapy in Patients with Chronic Hepatitis B
Objective Tenofovir alafenamide (TAF) is a new prodrug of tenofovir that is widely used in chronic hepatitis B (CHB) patients, and its side effects have rarely been reported. We aimed to evaluate the incidence of side ef...
Human Glioma Nude Mouse Xenograft Model in situ
Backgrounds Surgery and chemotherapy are difficult because of the specific location of the glioma. The establishment of a suitable in situ model of glioma is the premise of the treatment of glioma. 8 week-old female BALB...
Plasma Exchange to Treat Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome after Anti-CD19 Chimeric Antigen Receptor-T Cell Infusion: A Case Report
Adoptive cell immunotherapy with chimeric antigen receptor-T (CAR-T) cells has shown remarkable clinical out-comes. However, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICA...